TevaGastrim for Stem Cell Mobilization Sibling Donors
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to evaluate the efficacy of TevaGastrim which is a biosimilar
version of Filgrastim recombinant human G-CSF (G-CSF) in mobilizing sufficient number of stem
cells from normal sibling donors for allogeneic stem cell transplantation.